Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-18
DOI
10.1038/s41375-020-0797-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy
- (2019) Anthony R. Mato et al. HAEMATOLOGICA
- Clinical characteristics and outcomes of Richter transformation: Experience of 204 patients from a single center
- (2019) Yucai Wang et al. HAEMATOLOGICA
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
- (2019) Kirsten Fischer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
- (2019) Jan A. Burger et al. LEUKEMIA
- PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT)
- (2018) Rong He et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales
- (2018) Birgit Federmann et al. ANNALS OF HEMATOLOGY
- Biology and treatment of Richter syndrome
- (2018) Davide Rossi et al. BLOOD
- PD-1 is highly expressed by neoplastic B-cells in Richter transformation
- (2018) Amir Behdad et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
- (2018) Paula Cramer et al. LANCET ONCOLOGY
- CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia
- (2018) Julia von Tresckow et al. LEUKEMIA
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
- (2016) Barbara Eichhorst et al. LANCET ONCOLOGY
- Richter transformation of CLL
- (2016) Nitin Jain et al. Expert Review of Hematology
- Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation
- (2014) Petra Langerbeins et al. AMERICAN JOURNAL OF HEMATOLOGY
- Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
- (2014) S. Stilgenbauer et al. BLOOD
- How we treat Richter syndrome
- (2014) S. A. Parikh et al. BLOOD
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients
- (2013) Sameer A. Parikh et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
- (2013) Apostolia M. Tsimberidou et al. Clinical Lymphoma Myeloma & Leukemia
- Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2012) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
- (2011) D. Rossi et al. BLOOD
- Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature
- (2011) Bruno Bockorny et al. BRITISH JOURNAL OF HAEMATOLOGY
- Biological and clinical significance of stereotyped B-cell receptors in chronic lymphocytic leukemia
- (2010) D. Rossi et al. HAEMATOLOGICA
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
- (2009) B. F. Eichhorst et al. BLOOD
- De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience
- (2009) C. S. Tam et al. BLOOD
- Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome
- (2009) D. Rossi et al. CLINICAL CANCER RESEARCH
- Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
- (2009) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome
- (2008) Davide Rossi et al. BRITISH JOURNAL OF HAEMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now